EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach a higher concentration in brain tissues. Various reports and small studies ...

The optimal selection of patients with non-small-cell lung cancer (NSCLC) for treatment with oral small-molecule tyrosine kinase inhibitors (TKIs) has been an area of great debate. Inhibiting EGFR ...

2024 年 12 月 6 日 - 8 日，欧洲肿瘤内科学会亚洲年会（ESMO Asia）将在新加坡盛大召开。本届会议将汇聚全球专家学者，集中展示和讨论肿瘤学领域的最新科学和临床进展，为肿瘤领域带来一场学术盛宴。此次会议中，「Dato-DXd ...

The advancement of EGFR inhibitors for cancer therapy has moved rapidly in the broad context of oncology therapeutics. The fact that four new EGFR inhibitors (gefitinib, cetuximab, erlotinib ...

在国家自然科学基金项目（批准号：82072784、82072785、82273304、82303437）等资助下，复旦大学附属华山医院毛颖教授、花玮教授和迟喻丹研究员团队在免疫逃逸参与肺癌脑转移靶向治疗耐药研究方面取得进展。研究成果以“通过CTLA4 ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC).

The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.

Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

China’s drug regulator approved Alpha Biopharma Ltd.’s EGFR tyrosine kinase inhibitor (TKI), Zorifer (zorifertinib hydrochloride tablets; AZD-3759), as a first-line treatment for EGFR-mutated ...

Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell ...